ArticleClinical & experimental metastasis1996
Genistein-stimulated adherence of prostate cancer cells is associated with the binding of focal adhesion kinase to beta-1-integrin.
Article in Clinical & experimental metastasis, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 79 citations in OpenAlex.
- MEK4 function, genistein treatment, and invasion of human prostate cancer cells.Journal of the National Cancer Institute · 2009Trial
- The role of isoflavones in augmenting the effects of radiotherapy.Frontiers in oncology · 2022Review
- Prostate cancer metastasis and soy isoflavones: a dogfight over a bone.EXCLI journal · 2019Review
- Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin DAmerican journal of clinical and experimental urology · 2016Article
- Genistein inhibits human prostate cancer cell detachment, invasion, and metastasis.The American journal of clinical nutrition · 2014Review
- The role of integrin-β/FAK in cyclic mechanical stimulation in MG-63 cells.International journal of clinical and experimental pathology · 2014Article
- Seoritae extract reduces prostate weight and suppresses prostate cell proliferation in a rat model of benign prostate hyperplasia.Evidence-based complementary and alternative medicine : eCAM · 2014Article
- Perspectives on the role of isoflavones in prostate cancer.The AAPS journal · 2013Review
- Membrane fluidity, invasiveness and dynamic phenotype of metastatic prostate cancer cells after treatment with soy isoflavones.The Journal of membrane biology · 2013Article
- Estrogenic compounds are not always cardioprotective and can be lethal in males with genetic heart disease.Endocrinology · 2012Article
- Pituitary adenylate cyclase-activating polypeptide causes increased tyrosine phosphorylation of focal adhesion kinase and paxillin.Journal of molecular neuroscience : MN · 2012Article
- Src kinase mediates productive endocytic sorting of reovirus during cell entry.Journal of virology · 2011Article
- Endocytosis of titanium dioxide nanoparticles in prostate cancer PC-3M cells.Nanomedicine : nanotechnology, biology, and medicine · 2011Article
- Inhibition of cancer cell invasion and metastasis by genistein.Cancer metastasis reviews · 2010Review
- Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.Carcinogenesis · 2010Article
- Article
- Nonreceptor tyrosine kinases in prostate cancer.Neoplasia (New York, N.Y.) · 2007Review
- Phenoxodiol: isoflavone analog with antineoplastic activity.Current oncology reports · 2006Review
- Genistein inhibits invasive potential of human hepatocellular carcinoma by altering cell cycle, apoptosis, and angiogenesis.World journal of gastroenterology · 2005Article
- Flavonoid compounds in maintenance of prostate health and prevention and treatment of cancer.Molecular biotechnology · 2005Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The isoflavinoid genistein is a protein-tyrosine kinase inhibitor which has been identified as a putative cancer prevention agent. Its consumption is associated with a low incidence of clinical metastatic prostate cancer in the face of a sustained high incidence of organ-confined prostate cancer. We therefore undertook studies to examine genistein's effect upon cell adhesion as one possible mechanism by which it could be acting as an antimetastatic agent. A morphogenic analysis revealed that genistein caused cell flattening in a variety of cell lines: PC3-M, PC3, and DU-145 prostate carcinoma cells, as well as MCF-7 breast carcinoma cells. Mechanistic studies focused on the highly metastatic PC3-M cell line, and revealed that cell flattening was accompanied by an increase in cell adhesion. Further investigations demonstrated that focal adhesion kinase (FAK) accumulated in areas of focal cell attachment, and that this accumulation occurred only when cells were actively undergoing genistein-mediated morphologic change. Concurrent formation of a complex between the cell attachment molecule, beta-1-integrin, and FAK was shown to occur, and to correlate with transient activation of FAK activity. Genistein is presented as a novel investigative tool for use in the study of molecular events involved in the process of cell adhesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.